Using artificial intelligence to analyze the bacteria in a person’s gut microbiome shows promise as a new screening method for cardiovascular disease (CVD), according to preliminary research to be presented Sept. 10-13, 2020, at the virtual American Heart Association’s Hypertension 2020 Scientific Sessions. The meeting is a premier global exchange for clinical and basic researchers focusing on recent advances in hypertension research. The full study published simultaneously today in Hypertension, an American Heart Association journal.
Recent studies have found a link between gut microbiota, the microorganisms in human digestive tracts, and CVD, which is the leading cause of mortality worldwide. Gut microbiota is highly variable between individuals, and differences in gut microbial compositions between people with and without CVD have been reported.
“Based on our previous research linking gut microbiota to CVD in animal models, we designed this study to test whether it is possible to screen for CVD in humans using artificial intelligence screening of stool samples,” said Bina Joe, Ph.D., FAHA, the study director, Distinguished University Professor and Chairwoman of the department of physiology and pharmacology at the University of Toledo in Toledo, Ohio. “Gut microbiota has a profound effect on cardiovascular function, and this could be a potential new strategy for evaluation of cardiovascular health.”
Researchers used data from the American Gut Project (an open platform for microbiome research based in the United States) to analyze microbial composition of stool samples with state-of-the-art machine learning modeling. Nearly 1,000 samples were analyzed, and approximately half of the samples were from people with CVD. The model was able to identify different clusters of gut bacteria that could potentially help identify individuals with existing CVD and without CVD.
Among the bacteria identified: